MEI Pharma, Inc.
MEIP
$2.04
$0.042.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | 33.76% | 13.58% | 16.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | 33.76% | 13.58% | 16.10% |
| Cost of Revenue | -53.24% | -57.26% | -67.42% | -69.62% | -30.75% |
| Gross Profit | -121.58% | -119.98% | 44,968.18% | 340.70% | 68.80% |
| SG&A Expenses | -54.23% | -36.87% | -29.02% | 1.38% | 2.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -53.38% | -46.83% | -52.05% | -56.46% | -50.16% |
| Operating Income | -235.39% | -185.65% | 178.36% | 160.71% | 140.59% |
| Income Before Tax | -292.59% | -213.22% | 155.84% | 169.06% | 163.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -292.59% | -213.22% | 155.84% | 169.06% | 163.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -292.59% | -213.22% | 155.84% | 169.06% | 163.69% |
| EBIT | -235.39% | -185.65% | 178.36% | 160.71% | 140.59% |
| EBITDA | -229.72% | -183.24% | 180.45% | 162.20% | 141.72% |
| EPS Basic | -292.59% | -213.22% | 155.84% | 169.03% | 163.62% |
| Normalized Basic EPS | -201.00% | -171.64% | 203.49% | 178.00% | 175.27% |
| EPS Diluted | -292.59% | -213.22% | 155.84% | 169.03% | 163.62% |
| Normalized Diluted EPS | -201.00% | -171.64% | 203.49% | 178.00% | 175.27% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.03% | 0.06% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.03% | 0.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |